Opus Genetics: A Genuine Study Win, and a Valuation Case Still Waiting on Its Bridge

Opus Genetics just delivered the readout a gene-therapy investor waits months for. Every one of the five patients on the low dose of its BEST1 trial showed measurable improvement in at least one measure of vision, the FDA signed off on a path to a pivotal trial, and the company says it can start Phase 3 dosing in 2027. The shares jumped, then settled near $5.70. Seen one way, the case is almost too simple: the study worked, so the stock deserves to be worth more. The useful question is narrower than that. What the market did next — and how this company actually pays for its promise — says more about whether a higher valuation is deserved than the headline does.

What the "resounding success" actually was

The data, announced September 9, came from Cohort 1 of BIRD-1, a Phase 1/2 trial of OPGx-BEST1 in adults with two forms of BEST1-associated retinal disease: three patients with Best vitelliform macular dystrophy and two with autosomal recessive bestrophinopathy. All five received the same low dose by a single subretinal injection. After three to six months of follow-up, all five showed clinically meaningful improvement in at least one measure of visual function. Best-corrected visual acuity improved in three of five, structural improvements were seen in four of five, and among the four patients whose microperimetry was evaluable, three showed meaningful gains in retinal sensitivity. There were no serious adverse events, no dose-limiting toxicities, and no intraocular inflammation.

Balanced against that is the size of the sample. This is five patients at the lowest dose, read out over a few months. It de-risks a mechanism, not a product. The FDA's Type C meeting in August added real weight: the agency aligned on a pivotal endpoint — an improvement of at least 3 decibels on microperimetry in at least five prespecified locations, combined with a patient-reported outcome, in a randomized, controlled trial — and reached alignment on manufacturing. That is a concrete, checkable step that turns a vague "it might work" into a test with a specific bar. But the bar is still ahead, and BEST1 disease is a rare one: roughly 21,800 patients worldwide, about 8,400 of them in the U.S., with no approved treatment today.

This is the point where a stock like this usually asks you to trust the arc. Hold that thought, because the arc has a financial shape worth inspecting first.

The bridge this story doesn't have

In my normal frame, a beaten-down stock gets interesting when the improvement shows up in the cash flow before the crowd trusts it. The hard proof I want is free cash flow, or a credible path to it. This company has none — it is clinical-stage, with no revenue, no earnings, and no free cash flow to bridge anything. When that anchor is absent, the honest move is to say so plainly, name what actually carries the case, and admit the higher uncertainty that comes with the swap.

What carries the case here is clinical probability, and clinical probability is paid for with other people's money. As of the last report the company said its cash covers operations into 2029, built through ordinary-share placements — $23 million late in 2025, another $25 million in February 2026 — and through a financing with Oberland Capital structured as notes rather than common stock. The structure is worth understanding, because "non-dilutive" in biotech usually means something smaller than it sounds. The agreement funds the first $35 million of a $155 million facility at a floating interest rate around 4.1%, matures in seven years, is interest-only for six, capitalizes half its early interest into the principal, and gives Oberland an option to convert up to 10% of the principal into stock at $6.72 a share. No new common shares trade hands today, true. But the interest payments, the capitalized principal, and the conversion kicker are still claims stacked ahead of whatever cash the equity holders will ever see — on top of a history of dilution at lower prices.

Strip the jargon and this is the whole thesis in one sentence: a business with no cash flow is betting borrowed and sold equity on a handful of clinical outcomes that sit years from any revenue. That is a perfectly legitimate risk to take on the long side of an experiment. It is not, by itself, a reason the stock is worth more today.

What would actually earn the higher mark

The market seems to understand the difference. On the data day the shares popped, then went quiet around $5.70 — about a $360 million market capitalization for a company with no revenue. A clean, low-dose readout was close to the expected outcome, and the street appears to be waiting for the evidence that would actually move the case.

That evidence has a specific shape over the next twelve months. Cohort 2 is already running at a dose three times higher, over-enrolled at eight patients, with dosing expected to finish in the fourth quarter of 2026 and three-month results around the second quarter of 2027. The real test is whether the low-dose signal survives the higher dose without a safety problem, and — more important — whether the microperimetry gains hold and translate into the patient-reported benefit the FDA accepted as part of the endpoint. Behind that sits the LCA5 program, its registrational trial fully enrolled, dosing planned for the fourth quarter of 2026 with topline data by the end of 2027.

The condition that breaks the case is equally specific. A higher dose that trades efficacy for safety trouble, a microperimetry gain that fades, or a randomized, controlled Phase 3 that misses the agreed 3-decibel bar would undo the higher-dose narrative at the exact step the FDA just defined. So would the quieter risk that the next Phase 3, years from revenue, has to be funded through more dilution or harder debt terms. Competition in retinal gene therapy is real, and durability — whether a restored signal holds for years, not quarters — is the open question no three-month readout can answer.

I can be wrong again; the mechanism might prove durable, and the bigger cohorts could confirm it. The setup is that real de-risking happened, and the odds genuinely improved. But a higher valuation is earned by evidence, not promised by a good day in the clinic. Let Cohort 2 confirm the dose-response, let the randomized Phase 3 get green-lit with a functional gain patients can feel, and this becomes a story the market has to start pricing as a product rather than a bet. Until those proof points land, the patient move is the one that pays for the waiting — not a bid that front-runs results this early-stage company has not yet produced.